10 Jul Dan Chateau
Bio
Dr. Dan Chateau joined the Manitoba Centre for Health Policy (MCHP) in 2001 as a postdoctoral fellow after completing his doctoral work at the University of Western Ontario. He has been with the Centre as a research scientist since 2004, and also worked with the Faculty of Medicine as a biostatistician for a decade. Dr. Chateau is an expert in many different analytical techniques using large administrative databases and has been part of the CNODES Methods team and Manitoba site team since 2011. He also joined the CNODES steering committee in 2014.
Dr. Chateau has authored or co-authored over 70 papers and reports covering a wide variety of clinical and population health/health services use topics. Recent work with MCHP has included the evaluation of a population level RCT with physicians of an intervention to reduce inappropriate prescription practices. This audit and feedback intervention included an analysis of administrative drug data. In addition to work with CNODES and the Manitoba Centre for Health Policy, Dr. Chateau is part of the leadership group of a $2 million CIHR programmatic grant examining health equity measures, and the impact of interventions/policies on health equity.
CNODES Projects
Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis
Methods LeadUse of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Analyst, Manitoba- Methods Lead
Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort study
Site Investigator, ManitobaObservational studies of drug safety in multi-database studies: Methodological challenges and opportunities
Collaborator, Manitoba- Methods Lead
Prescription ranitidine use and population exposure in 6 Canadian provinces, 1996 to 2019: a serial cross-sectional analysis
Site Investigator, ManitobaSafety of bowel cleansers when combined with bisacodyl stimulant laxative
Site Investigator, ManitobaUse of systemic oral fluoroquinolones in Canada
Methods LeadFluoroquinolone use for uncomplicated urinary tract infections in women: a retrospective cohort study
Methods LeadFluoroquinolone use for acute bacterial sinusitis
Methods LeadComparative effectiveness of fluoroquinolone antibiotic use in uncomplicated acute exacerbations of chronic obstructive pulmonary disease: a multi-cohort study
Methods LeadValsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study
Site Investigator, ManitobaExtreme restriction design as a method for reducing confounding by indication in pharmacoepidemiologic research
Collaborator, ManitobaPatterns of steroid utilization in COVID-19 patients
Site Investigator, ManitobaChanges in the dispensing of opioid medications in Canada following the introduction of a tamper-deterrent formulation of long-acting oxycodone: a time series analysis
Project Co-Lead, Manitoba